GH1 and hematocrit: However, 6 of the 8 cases of papillary carcinoma (75%) were treated with GH, while only 4 of the 8 cases (50%) had HT, thus excluding the potential role of HT in the increased incidence of papillary thyroid carcinoma in these patients [53].